Send to

Choose Destination
See comment in PubMed Commons below
Dermatol Ther. 2013 May-Jun;26(3):263-6. doi: 10.1111/j.1529-8019.2013.01548.x. Epub 2013 Mar 13.

Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases.

Author information

Department of Dermatology, No. 1 Hospital of China Medical University, Shenyang, China.


Primary cutaneous amyloidosis (PCA), either familial or sporadic, poses a therapeutic challenge. We conducted an open trial using thalidomide to treat three cases of familial and three cases of sporadic PCA, at initial dose of 100 mg/day. Dosage adjustment was made according to improvement of symptoms or patient's own choice. All except one sporadic case experienced moderate to significant relief on the symptoms of itching, over an observational period of 8 weeks by visual analog score (from 8.08 ± 0.88 to 1.60 ± 0.68, on average) as well as clinical amelioration of symptoms. Side effects included fatigue, drowsiness, numbness, and facial and leg edema in some of the patients. From the present observation, it seems that thalidomide is a promising drug to treat PCA.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center